Parenteral Delivery of Peptides and Proteins - Challenges in Delivery of Therapeutic Genomics and Proteomics - page 591

[17] Ali M, Manolios N. Peptide delivery systems. Lett Pept Sci 2002;8:289-94.
[18] Patten PA, Schellekens H. The immunogenicity of biopharmaceuticals. Lessons learned
and consequences for protein drug development. Dev Biol Stand 2003;112:81-97.
[19] Hermeling S, Crommelin DJ, Schellekens H, Jiskoot W. Structure immunogenicity rela-
tionships of therapeutic proteins. Pharm Res 2004;21:897-903.
[20] Banga AK. Parenteral controlled delivery and pharmacokinetics of therapeutic peptides.
In: Banga AK, editor. Therapeutic peptides and proteins: formulation, processing, and
delivery systems. 2nd ed. Boca Raton, FL: CRC Press; 2006. p. 177-227.
[21] Gloff CA, Benet LZ. Pharmacokinetics and protein therapeutics. Adv Drug Delivery Rev
1990;4:359-86.
[22] Colburn WA. Peptide, peptoid and protein pharmacokinetics/pharmacodynamics. In:
Garzone P, Colburn W, Mokotoff M, editors. Pharmacokinetics and pharmacodynamic.
Peptides, peptoids and proteins, vol. 3. Cincinnati OH: Harvey Whitney Books; 1991.
p. 94-115.
[23] Hashida M, Takakura Y. Pharmacokinetics in design of polymeric drug delivery systems.
J Control Release 1994;31:163-71.
[24] Brown SA, Nelson RW, Bottoms GD. Models for the pharmacokinetics and pharmacody-
namics of insulin in alloxan-induced diabetic dogs. J Pharm Sci 1987;76:295-9.
[25] Hooper SA, Bowsher RR, Howey DC. Pharmacokinetics and pharmacodynam-
ics of intravenous regular human insulin. In: Garzone PD, Colburn WA, Mokotoff M,
editors. Pharmacokinetics and pharmacodynamics. Peptides, peptoids and proteins,
vol. 3. New York: CRC Press; 1991. p. 128-37.
[26] Wills RJ, Ferraiolo BL. The role of pharmacokinetics in the development of biotechno-
logically derived agents. Clin Pharmacokinet 1992;23:406-14.
[27] Working PK. Potential effects of antibody induction by protein drugs. In: Ferraiolo BL,
Mohler MA, Gloff CA, editors. Pharmaceutical biotechnology—protein pharmacokinet-
ics and metabolism, vol. 1. New York, NY: Plenum Press; 1992. p. 73-92.
[28] Ferraiolo BL, Fuller GB, Burnett B, Chan E. Pharmacokinetics of recombinant human
interferon- in the rhesus monkey after intravenous, intramuscular, and subcutaneous
administration. J Biol Response Modif 1988;7:115-22.
[29] Mordenti J. Man versus beast: pharmacokinetic scaling in mammals. J Pharm Sci
1986;75:1028-40.
[30] Hashida M, Nishikawa M, Yamashita F, Takakura Y. Targeting delivery of protein drugs
by chemical modification. Drug Dev Ind Pharm 1994;20:581-90.
[31] Takakura Y, Mihara K, Hashida M. Control of the disposition profiles of proteins in the
kidney via chemical modification. J Control Release 1994;28:111-9.
[32] Caliceti P, Veronese FM. Pharmacokinetic and biodistribution properties of poly (ethyl-
ene glycol)-protein conjugates. Adv Drug Delivery Rev 2003;55:1261-77.
[33] Richards AA, Colgrave ML, Zhang J, Webster J, Simpson F, Preston E, et al. Sialic acid
modification of adiponectin is not required for multimerization or secretion but deter-
mines half-life in circulation. Mol Endocrinol 2010;24:229-39.
[34] Martynov AV, Smelyanskaya MV. Antiproliferative properties of chemically modified
recombinant IFN-2b. J Interferon Cytokine Res 2005;25:414-17.
[35] Ivona B, Harry WM, Christoph S, Pilar M. The European NanoBioPharmaceutics
Research Initiative Delivery of peptide and protein drugs over the blood-brain barrier.
Prog Neurobiol 2009;87:212-51.
[36] Ulrich B, Takayoshi Y, William M. Delivery of peptides and proteins through the blood-
brain barrier. Adv Drug Delivery Rev 1999;46:247-79.
[37] Pardridge WM. Blood-brain barrier biology and methodology. J NeuroVirol 1999;5:556-69.